DrugPatentWatch Database Preview

Details for Patent: 8,343,130

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,343,130 protect, and when does it expire?

Patent 8,343,130 protects SUMAVEL DOSEPRO and is included in one NDA.

This patent has nine patent family members in six countries.

Summary for Patent: 8,343,130

Title:	Needleless injector
Abstract:	A needleless injector has a syringe body having an opening at one end, a piston housed within the syringe body for urging a liquid within the syringe body through the opening and a ram for driving the piston. A shock absorbing component is provided for reducing an initial transfer of force from the ram to the piston. The initial rate of pressure increase on the liquid is reduced, thereby controlling the rate of collapse of gas bubbles in the liquid.
Inventor(s):	Green; Terry (Norfolk, GB)
Assignee:	Zogenix, Inc. (Emeryville, CA)
Application Number:	13/088,140
Patent Claim Types: see list of patent claims	Use; Dosage form; Delivery; Formulation;

Drugs Protected by US Patent 8,343,130

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Endo Ventures Ltd	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 8,343,130

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0125506.6	Oct 24, 2001

International Family Members for US Patent 8,343,130

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2464459
Germany	60214870
European Patent Office	1439872
United Kingdom	0125506
Japan	2005506153
Japan	2010046509
Japan	4688416